**Core Concept**
The question is testing the student's knowledge of the mechanism of action of antiglaucoma medications, specifically those that decrease aqueous humor production. Aqueous humor is a clear fluid produced in the eye, and its production is regulated by the ciliary body. The correct answer will be a medication that targets the ciliary body or the pathways involved in aqueous humor production.

**Why the Correct Answer is Right**
The correct answer is a carbonic anhydrase inhibitor (CAI). CAIs work by inhibiting the enzyme carbonic anhydrase, which is involved in the production of bicarbonate and the subsequent absorption of sodium and water in the ciliary body. By inhibiting this enzyme, CAIs decrease the production of aqueous humor, thereby lowering intraocular pressure (IOP). This is a key mechanism of action for medications such as acetazolamide and dorzolamide.

**Why Each Wrong Option is Incorrect**
* **Option A:** This option should be a medication that increases aqueous outflow, such as a beta-blocker (e.g., timolol) or a prostaglandin analog (e.g., latanoprost). These medications work by decreasing the production of aqueous humor or increasing its outflow, but they do not decrease aqueous formation directly.
* **Option B:** This option should be a medication that increases aqueous outflow, such as a miotic or a cholinergic agonist (e.g., pilocarpine). These medications work by increasing the outflow of aqueous humor, but they do not decrease aqueous formation directly.
* **Option D:** This option should be a medication that has an unknown or indirect effect on aqueous humor production, such as a non-selective alpha agonist (e.g., apraclonidine). While these medications can decrease IOP, their mechanism of action is not primarily through decreasing aqueous formation.

**Clinical Pearl / High-Yield Fact**
Carbonic anhydrase inhibitors are a useful class of medications for managing glaucoma, particularly in patients who are intolerant of beta-blockers or prostaglandin analogs. They can be used as monotherapy or in combination with other antiglaucoma medications to achieve adequate IOP control.

**Correct Answer:** C.